These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12892898)

  • 21. Persistent infection due to a small-colony variant of Burkholderia pseudomallei leads to PD-1 upregulation on circulating immune cells and mononuclear infiltration in viscera of experimental BALB/c mice.
    See JX; Chandramathi S; Abdulla MA; Vadivelu J; Shankar EM
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005702. PubMed ID: 28820897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the early host immune response to two widely diverse virulent strains of Burkholderia pseudomallei that cause acute or chronic infections in BALB/c mice.
    Amemiya K; Dankmeyer JL; Fetterer DP; Worsham PL; Welkos SL; Cote CK
    Microb Pathog; 2015 Sep; 86():53-63. PubMed ID: 26162294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A multi-resistant bacterium before the era of antibiotics: the agent of melioidosis].
    Buisson Y
    C R Biol; 2024 Mar; 346(S1):17-21. PubMed ID: 37655946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High HMGB1 level is associated with poor outcome of septicemic melioidosis.
    Charoensup J; Sermswan RW; Paeyao A; Promakhejohn S; Punasee S; Chularari C; Krabkraikaew S; Lertanekawattana S; Wongratanacheewin S
    Int J Infect Dis; 2014 Nov; 28():111-6. PubMed ID: 25263503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice.
    Su YC; Wan KL; Mohamed R; Nathan S
    Vaccine; 2010 Jul; 28(31):5005-11. PubMed ID: 20546831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of L-selectin expression in Burkholderia pseudomallei-infected monocytes invading the brain during murine melioidosis.
    Chen YS; Lin HH; Hsueh PT; Ni WF; Liu PJ; Chen PS; Chang HH; Sun DS; Chen YL
    Virulence; 2017 Aug; 8(6):751-766. PubMed ID: 27646437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis.
    Leakey AK; Ulett GC; Hirst RG
    Microb Pathog; 1998 May; 24(5):269-75. PubMed ID: 9600859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders.
    Barnes KB; Steward J; Thwaite JE; Lever MS; Davies CH; Armstrong SJ; Laws TR; Roughley N; Harding SV; Atkins TP; Simpson AJ; Atkins HS
    Int J Antimicrob Agents; 2013 Jun; 41(6):552-7. PubMed ID: 23517714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.
    Soontornpas C; Saraya S; Chulasiri M; Chindavijak B; Mootsikapun P
    Int J Antimicrob Agents; 2005 Nov; 26(5):403-7. PubMed ID: 16216470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility patterns of Burkholderia pseudomallei among melioidosis cases in Kedah, Malaysia.
    Hassan MR; Vijayalakshmi N; Pani SP; Peng NP; Mehenderkar R; Voralu K; Michael E
    Southeast Asian J Trop Med Public Health; 2014 May; 45(3):680-8. PubMed ID: 24974653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glyburide reduces bacterial dissemination in a mouse model of melioidosis.
    Koh GC; Weehuizen TA; Breitbach K; Krause K; de Jong HK; Kager LM; Hoogendijk AJ; Bast A; Peacock SJ; van der Poll T; Steinmetz I; Wiersinga WJ
    PLoS Negl Trop Dis; 2013; 7(10):e2500. PubMed ID: 24147174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting aminocoumarins for the treatment of melioidosis.
    Willcocks SJ; Cia F; Francisco AF; Wren BW
    Int J Antimicrob Agents; 2020 Jul; 56(1):106002. PubMed ID: 32361027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime resistance in Burkholderia pseudomallei: first report from India.
    Behera B; Prasad Babu TL; Kamalesh A; Reddy G
    Asian Pac J Trop Med; 2012 Apr; 5(4):329-30. PubMed ID: 22449529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.
    Casey WT; Spink N; Cia F; Collins C; Romano M; Berisio R; Bancroft GJ; McClean S
    Vaccine; 2016 May; 34(23):2616-21. PubMed ID: 27091689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand.
    Cheng AC; Limmathurotsakul D; Chierakul W; Getchalarat N; Wuthiekanun V; Stephens DP; Day NP; White NJ; Chaowagul W; Currie BJ; Peacock SJ
    Clin Infect Dis; 2007 Aug; 45(3):308-14. PubMed ID: 17599307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response.
    Cummings JE; Slayden RA
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005209. PubMed ID: 28081127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei.
    McCurdy S; Duffy E; Hickman M; Halasohoris S; Zumbrun SD
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073621. PubMed ID: 34339266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis.
    Weehuizen TA; Lankelma JM; De Jong HK; De Boer OJ; Roelofs JJ; Day NP; Gram H; De Vos AF; Wiersinga WJ
    Shock; 2016 Nov; 46(5):566-574. PubMed ID: 27219859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.
    Chierakul W; Anunnatsiri S; Short JM; Maharjan B; Mootsikapun P; Simpson AJ; Limmathurotsakul D; Cheng AC; Stepniewska K; Newton PN; Chaowagul W; White NJ; Peacock SJ; Day NP; Chetchotisakd P
    Clin Infect Dis; 2005 Oct; 41(8):1105-13. PubMed ID: 16163628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.